{"podcast":{"title":"Decera Clinical Education Oncology Podcast","slug":"decera-clinical-education-oncology-podcast-1302999","podcast_index_feed_id":1302999,"rss_url":"https://feeds.simplecast.com/GlfUTtJq","website_url":"https://oncologypodcast.simplecast.com","image_url":"https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/2d9bf1a9-d5c4-4079-9b3e-a531bfcf7774/3000x3000/decera-onc-podcast-show-icon.jpg?aid=rss_feed","author":"Decera Clinical Education","episode_count":253,"summary":"Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.","last_synced_at":"2026-07-15T02:18:52.844818+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999"},"episode":{"title":"From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL","slug":"from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll","published_at":"2026-03-11T16:56:12+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll","show_page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999","url":"https://oncologypodcast.simplecast.com/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll-dk0fFFb5","audio_url":"https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/8a9db931-2a92-41df-b0b3-398ca8b7dcaa/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=8a9db931-2a92-41df-b0b3-398ca8b7dcaa&feed=GlfUTtJq","summary":"This episode features Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discussing key conference highlights from the 2025 ASH Annual Meeting, with a focus on emerging BTK-targeted therapies in relapsed/refractory CLL. They share global perspectives on real-world use, sequencing strategies, safety considerations, and how new data may shape future clinical practice.","meta_description":"This episode features Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discussing key conference highlights from th…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1824,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}